现代技术术后放疗未改善可手术IIIA-N2期非小细胞肺癌生存
本研究基于美国国家癌症数据库2010—2018年数据,评估完全切除的IIIA-N2期非小细胞肺癌患者接受术后调强放疗(IMRT)是否与生存改善相关。共纳入3203例接受肺叶切除术的患者,经Kaplan-Meier分析、Cox比例风险分析和倾向性评分匹配分析,接受与未接受术后IMRT者的总生存无显著差异。
要点
- 完全切除的IIIA-N2期非小细胞肺癌患者中,术后IMRT与未行IMRT者总生存无显著差异。
- 该结论在未调整、多变量调整和倾向性评分匹配分析中一致。
- 不论是否接受诱导化疗,术后IMRT均未与生存改善相关。
核心结论
- 在完全切除的IIIA-N2期非小细胞肺癌患者中,无论是否接受诱导化疗,术后IMRT的使用与总生存改善均无显著相关。
研究设计与样本
- 基于美国国家癌症数据库2010—2018年的分析,纳入3203例接受肺叶切除术的IIIA-N2期非小细胞肺癌患者,采用Kaplan-Meier分析、Cox比例风险分析和倾向性评分匹配分析。
- 仅纳入接受IMRT(较新、适形度更高的放疗技术)的患者,手术切缘阳性者被排除。
主要发现
- 588例(18.4%)接受诱导化疗后肺叶切除术,2615例(82%)接受肺叶切除术后化疗。
- 在未调整、多变量调整和倾向性评分匹配分析中,接受与未接受术后IMRT的患者总生存均无显著差异。
- 在完全切除的IIIA-pN2期、先行肺叶切除术(未行诱导治疗)后接受单纯辅助化疗或辅助化疗联合术后IMRT的患者中,也进行了额外生存分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aims to evaluate whether postoperative radiotherapy using newer techniques (intensity-modulated radiotherapy [IMRT]) is associated with improved survival for patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) who underwent complete resection. METHODS: The overall survival of patients with stage IIIA-N2 NSCLC who received postoperative IMRT versus no postoperative IMRT following induction chemotherapy and lobectomy in the National Cancer Database from 2010-2018 was assessed via Kaplan-Meier analysis, Cox proportional hazards analysis and propensity score-matched analysis. Additional survival analyses were also conducted in patients with completely resected stage IIIA-pN2 NSCLC who had upfront lobectomy (without induction therapy) followed by adjuvant chemotherapy alone or adjuvant chemotherapy with postoperative IMRT. Only patients receiving IMRT, which is a newer, more conformal radiotherapy technique, were included. Patients with positive surgical margins were excluded. RESULTS: A total of 3203 patients with stage IIA-N2 NSCLC who underwent lobectomy were included. Five hundred eighty-eight (18.4%) patients underwent induction chemotherapy followed by lobectomy, and 2615 (82%) underwent lobectomy followed by chemotherapy. In unadjusted, multivariable-adjusted, and propensity score--matched analyses, there were no significant differences in overall survival between the patients who also received postoperative IMRT versus those who did not. CONCLUSIONS: In this national analysis, the use of postoperative IMRT was not associated with improved survival in patients with completely resected stage IIIA-N2 NSCLC with or without induction chemotherapy.
引用
- Predina J, Suliman R, Potter AL, et al. Postoperative radiotherapy with modern techniques does not improve survival for operable stage IIIA-N2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022. PMID: 36610886. doi:10.1016/j.jtcvs.2022.09.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。